ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

This study (ARTEMIS-102) is testing HS-20093 — an antibody-drug conjugate targeting B7-H3 — either alone or in combination with other cancer drugs, in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic NSCLC or another qualifying solid tumor - Your cancer has progressed after at least one prior standard therapy - You are in reasonably good health (ECOG score 0–1) - Your organ function meets required thresholds **You may NOT be eligible if...** - You have active brain metastases that are untreated - You have interstitial lung disease or active lung inflammation - You have had prior treatment with a B7-H3 targeted therapy - You are pregnant or breastfeeding - You have a serious active autoimmune condition Talk to your doctor to see if this trial is right for you.